Bengaluru-based 4baseCare has launched TARGT Indiegene, a population-specific tumour gene panel derived from whole exome and whole transcriptome data of over 1500 cancer patients across 28 different cancer types.

Most of the patients were presented with stage III/ IV disease, and presented with disease progression and had exhausted all the options in the standard of care.

The TARGT Indiegene cancer panel is based on insights generated from tumour tissues of Indian cancer patients resulting in better success rates using precision medicine in the management of cancer.

The insights from research have helped build the largest resource of mutational signatures identified in cancer patients in India. Research has provided insights into 1044 unique genes across 28 different cancer types with mutational landscape and associated mutations.

Dr Kumar Prabhash, Professor and Medical Oncologist at TMH, Mumbai and one of the collaborators for the project said, "The availability of TARGT Indiegene kind of a cancer gene panel validated on Indian patient tumour samples, the oncologists will have better decision making capability lead by science towards precision oncology solutions that will improve the affordability and timely availability of accurate gene-testing reports for cancer patients."